Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Targeted deletion of an NRL- and CRX-regulated alternative promoter specifically silences FERM and PDZ domain containing 1 (Frmpd1) in rod photoreceptors.

Campla CK, Mast H, Dong L, Lei J, Halford S, Sekaran S, Swaroop A.

Hum Mol Genet. 2018 Nov 15. doi: 10.1093/hmg/ddy388. [Epub ahead of print]

PMID:
30445545
2.

Novel homozygous splicing mutations in ARL2BP cause autosomal recessive retinitis pigmentosa.

Fiorentino A, Yu J, Arno G, Pontikos N, Halford S, Broadgate S, Michaelides M, Carss KJ, Raymond FL, Cheetham ME, Webster AR, Downes SM, Hardcastle AJ; NIHR-BioResource Rare Diseases Consortium; U.K. Inherited Retinal Dystrophy Consortium.

Mol Vis. 2018 Aug 31;24:603-612. eCollection 2018.

3.

Diabetic macular oedema: under-represented in the genetic analysis of diabetic retinopathy.

Broadgate S, Kiire C, Halford S, Chong V.

Acta Ophthalmol. 2018 Apr;96 Suppl A111:1-51. doi: 10.1111/aos.13678. Review.

4.

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.

Cook N, Basu B, Smith DM, Gopinathan A, Evans J, Steward WP, Palmer D, Propper D, Venugopal B, Hategan M, Anthoney DA, Hampson LV, Nebozhyn M, Tuveson D, Farmer-Hall H, Turner H, McLeod R, Halford S, Jodrell D.

Br J Cancer. 2018 Mar 20;118(6):793-801. doi: 10.1038/bjc.2017.495. Epub 2018 Feb 13.

5.

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.

Woodcock VK, Clive S, Wilson RH, Coyle VM, Stratford MRL, Folkes LK, Eastell R, Barton C, Jones P, Kazmi-Stokes S, Turner H, Halford S, Harris AL, Middleton MR.

Br J Cancer. 2018 Mar 20;118(6):770-776. doi: 10.1038/bjc.2017.484. Epub 2018 Feb 13.

6.

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.

Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, Byatte AJ, Kirillova N, Valle JW, Sharma SK, Chester KA, Westwood NB, Halford SER, Nabarro S, Wan S, Austin E, Hawkins RE.

Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436. doi: 10.1007/s00262-017-2034-7. Epub 2017 Jun 28.

7.

Has the NHS 111 urgent care telephone service been a success? Case study and secondary data analysis in England.

Pope C, Turnbull J, Jones J, Prichard J, Rowsell A, Halford S.

BMJ Open. 2017 Jun 2;7(5):e014815. doi: 10.1136/bmjopen-2016-014815.

8.

Unravelling the genetics of inherited retinal dystrophies: Past, present and future.

Broadgate S, Yu J, Downes SM, Halford S.

Prog Retin Eye Res. 2017 Jul;59:53-96. doi: 10.1016/j.preteyeres.2017.03.003. Epub 2017 Mar 29. Review.

PMID:
28363849
9.

Phenopolis: an open platform for harmonization and analysis of genetic and phenotypic data.

Pontikos N, Yu J, Moghul I, Withington L, Blanco-Kelly F, Vulliamy T, Wong TLE, Murphy C, Cipriani V, Fiorentino A, Arno G, Greene D, Jacobsen JOB, Clark T, Gregory DS, Nemeth AM, Halford S, Inglehearn CF, Downes S, Black GC, Webster AR, Hardcastle AJ; UKIRDC, Plagnol V.

Bioinformatics. 2017 Aug 1;33(15):2421-2423. doi: 10.1093/bioinformatics/btx147.

PMID:
28334266
10.

'The New Degree?' Constructing Internships in the Third Sector.

Leonard P, Halford S, Bruce K.

Sociology. 2016 Apr;50(2):383-399. Epub 2015 May 12.

11.

Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience.

Wong HH, Barton C, Acton G, McLeod R, Halford S.

Eur J Cancer. 2016 Oct;66:9-16. doi: 10.1016/j.ejca.2016.07.004. Epub 2016 Aug 8. Review.

PMID:
27514008
12.

The work, workforce, technology and organisational implications of the ‘111’ single point of access telephone number for urgent (non-emergency) care: a mixed-methods case study.

Turnbull J, Pope C, Rowsell A, Prichard J, Halford S, Jones J, May C, Lattimer V.

Southampton (UK): NIHR Journals Library; 2014 Feb.

13.

Characterization of CDH3-Related Congenital Hypotrichosis With Juvenile Macular Dystrophy.

Hull S, Arno G, Robson AG, Broadgate S, Plagnol V, McKibbin M, Halford S, Michaelides M, Holder GE, Moore AT, Khan KN, Webster AR.

JAMA Ophthalmol. 2016 Sep 1;134(9):992-1000. doi: 10.1001/jamaophthalmol.2016.2089.

PMID:
27386845
14.

Ladybird books and Teeth.

Halford S.

Dent Hist. 2016 Jul;61(2):97-99.

PMID:
29894048
15.

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.

Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R.

Br J Cancer. 2016 Jun 14;114(12):e21. doi: 10.1038/bjc.2016.133. Epub 2016 May 26. No abstract available.

16.

A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.

Rampling R, Peoples S, Mulholland PJ, James A, Al-Salihi O, Twelves CJ, McBain C, Jefferies S, Jackson A, Stewart W, Lindner J, Kutscher S, Hilf N, McGuigan L, Peters J, Hill K, Schoor O, Singh-Jasuja H, Halford SE, Ritchie JW.

Clin Cancer Res. 2016 Oct 1;22(19):4776-4785. Epub 2016 May 25.

17.

Hypotrichosis and juvenile macular dystrophy caused by CDH3 mutation: A candidate disease for retinal gene therapy.

Singh MS, Broadgate S, Mathur R, Holt R, Halford S, MacLaren RE.

Sci Rep. 2016 May 9;6:23674. doi: 10.1038/srep23674.

18.

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.

McCann KJ, Mander A, Cazaly A, Chudley L, Stasakova J, Thirdborough S, King A, Lloyd-Evans P, Buxton E, Edwards C, Halford S, Bateman A, O'Callaghan A, Clive S, Anthoney A, Jodrell DI, Weinschenk T, Simon P, Sahin U, Thomas GJ, Stevenson FK, Ottensmeier CH.

Clin Cancer Res. 2016 Oct 1;22(19):4827-4836. doi: 10.1158/1078-0432.CCR-15-2507. Epub 2016 Apr 18.

19.

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.

Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R.

Br J Cancer. 2016 Mar 29;114(7):723-30. doi: 10.1038/bjc.2016.41. Epub 2016 Mar 22. Erratum in: Br J Cancer. 2016 Jun 14;114(12):e21.

20.

What if we made stratified medicine work for patients?

Britten N, Pope C, Halford S, Richeldi L.

Lancet Respir Med. 2016 Jan;4(1):8-10. doi: 10.1016/S2213-2600(15)00499-3. No abstract available.

PMID:
26762661
21.

Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?

Wong HH, Halford S.

Lancet Oncol. 2015 Oct;16(13):1287-8. doi: 10.1016/S1470-2045(15)00248-X. No abstract available.

PMID:
26433816
22.

Isoforms of Melanopsin Mediate Different Behavioral Responses to Light.

Jagannath A, Hughes S, Abdelgany A, Pothecary CA, Di Pretoro S, Pires SS, Vachtsevanos A, Pilorz V, Brown LA, Hossbach M, MacLaren RE, Halford S, Gatti S, Hankins MW, Wood MJ, Foster RG, Peirson SN.

Curr Biol. 2015 Sep 21;25(18):2430-4. doi: 10.1016/j.cub.2015.07.071. Epub 2015 Aug 27.

23.

Author reply: To PMID 24480711.

Halford S, Liew G, Mackay DS, Sergouniotis PI, Holt R, Broadgate S, Volpi EV, Ocaka L, Robson AG, Holder GE, Moore AT, Michaelides M, Webster AR.

Ophthalmology. 2015 Apr;122(4):e22. doi: 10.1016/j.ophtha.2014.08.041. No abstract available.

PMID:
25797088
24.

Identification of rod- and cone-specific expression signatures to identify candidate genes for retinal disease.

Holt R, Brown L, Broadgate S, Butler R, Jagannath A, Downes S, Peirson S, Halford S.

Exp Eye Res. 2015 Mar;132:161-73. doi: 10.1016/j.exer.2015.01.002. Epub 2015 Jan 9.

PMID:
25579607
25.

The shifting politics in multilateral development and human rights negotiations and the absence of accountability.

Halford S, Prasad S.

Reprod Health Matters. 2014 Nov;22(44):109-13. doi: 10.1016/S0968-8080(14)44813-4. No abstract available.

26.

The hypothalamic photoreceptors regulating seasonal reproduction in birds: a prime role for VA opsin.

García-Fernández JM, Cernuda-Cernuda R, Davies WI, Rodgers J, Turton M, Peirson SN, Follett BK, Halford S, Hughes S, Hankins MW, Foster RG.

Front Neuroendocrinol. 2015 Apr;37:13-28. doi: 10.1016/j.yfrne.2014.11.001. Epub 2014 Nov 22. Review.

27.

A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.

Moreno L, Marshall LV, Pearson AD, Morland B, Elliott M, Campbell-Hewson Q, Makin G, Halford SE, Acton G, Ross P, Kazmi-Stokes S, Lock V, Rodriguez A, Lyons JF, Boddy AV, Griffin MJ, Yule M, Hargrave D.

Clin Cancer Res. 2015 Jan 15;21(2):267-73. doi: 10.1158/1078-0432.CCR-14-1592. Epub 2014 Nov 4.

28.

Cyborg practices: call-handlers and computerised decision support systems in urgent and emergency care.

Pope C, Halford S, Turnbull J, Prichard J.

Health Informatics J. 2014 Jun;20(2):118-26. doi: 10.1177/1460458213486470.

PMID:
24810726
29.

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.

Glasspool RM, Brown R, Gore ME, Rustin GJ, McNeish IA, Wilson RH, Pledge S, Paul J, Mackean M, Hall GD, Gabra H, Halford SE, Walker J, Appleton K, Ullah R, Kaye S; Scottish Gynaecological Trials Group.

Br J Cancer. 2014 Apr 15;110(8):1923-9. doi: 10.1038/bjc.2014.116. Epub 2014 Mar 18.

30.

TstI, a Type II restriction-modification protein with DNA recognition, cleavage and methylation functions in a single polypeptide.

Smith RM, Pernstich C, Halford SE.

Nucleic Acids Res. 2014 May;42(9):5809-22. doi: 10.1093/nar/gku187. Epub 2014 Mar 14.

31.

What's the big fuss about 'big data'?

Pope C, Halford S, Tinati R, Weal M.

J Health Serv Res Policy. 2014 Apr;19(2):67-8. doi: 10.1177/1355819614521181. Epub 2014 Mar 4. No abstract available.

PMID:
24594859
32.

Detailed phenotypic and genotypic characterization of bietti crystalline dystrophy.

Halford S, Liew G, Mackay DS, Sergouniotis PI, Holt R, Broadgate S, Volpi EV, Ocaka L, Robson AG, Holder GE, Moore AT, Michaelides M, Webster AR.

Ophthalmology. 2014 Jun;121(6):1174-84. doi: 10.1016/j.ophtha.2013.11.042. Epub 2014 Jan 28.

PMID:
24480711
33.

A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.

Horsley L, Cummings J, Middleton M, Ward T, Backen A, Clamp A, Dawson M, Farmer H, Fisher N, Halbert G, Halford S, Harris A, Hasan J, Hogg P, Kumaran G, Little R, Parker GJ, Potter P, Saunders M, Roberts C, Shaw D, Smith N, Smythe J, Taylor A, Turner H, Watson Y, Dive C, Jayson GC; Cancer Research UK Drug Development Office Phase I clinical trial.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1343-52. doi: 10.1007/s00280-013-2320-9. Epub 2013 Oct 20.

PMID:
24141375
34.

Accessibility, reactivity, and selectivity of side chains within a channel of de novo peptide assembly.

Burton AJ, Thomas F, Agnew C, Hudson KL, Halford SE, Brady RL, Woolfson DN.

J Am Chem Soc. 2013 Aug 28;135(34):12524-7. doi: 10.1021/ja4053027. Epub 2013 Aug 13.

PMID:
23924058
35.

Using computer decision support systems in NHS emergency and urgent care: ethnographic study using normalisation process theory.

Pope C, Halford S, Turnbull J, Prichard J, Calestani M, May C.

BMC Health Serv Res. 2013 Mar 23;13:111. doi: 10.1186/1472-6963-13-111.

36.

Organization of the BcgI restriction-modification protein for the cleavage of eight phosphodiester bonds in DNA.

Smith RM, Marshall JJ, Jacklin AJ, Retter SE, Halford SE, Sobott F.

Nucleic Acids Res. 2013 Jan 7;41(1):391-404. doi: 10.1093/nar/gks1023. Epub 2012 Nov 11.

37.

Organization of the BcgI restriction-modification protein for the transfer of one methyl group to DNA.

Smith RM, Jacklin AJ, Marshall JJ, Sobott F, Halford SE.

Nucleic Acids Res. 2013 Jan 7;41(1):405-17. doi: 10.1093/nar/gks1000. Epub 2012 Nov 11.

38.

Homozygous deletion in CDH3 and hypotrichosis with juvenile macular dystrophy.

Halford S, Holt R, Németh AH, Downes SM.

Arch Ophthalmol. 2012 Nov;130(11):1490-2. doi: 10.1001/archophthalmol.2012.708. No abstract available.

PMID:
23143461
39.

Reconfiguring the emergency and urgent care workforce: mixed methods study of skills and the everyday work of non-clinical call-handlers in the NHS.

Turnbull J, Prichard J, Halford S, Pope C, Salisbury C.

J Health Serv Res Policy. 2012 Oct;17(4):233-40. doi: 10.1258/jhsrp.2012.011141. Epub 2012 Sep 28.

PMID:
23024183
40.

Differential expression of melanopsin isoforms Opn4L and Opn4S during postnatal development of the mouse retina.

Hughes S, Welsh L, Katti C, González-Menéndez I, Turton M, Halford S, Sekaran S, Peirson SN, Hankins MW, Foster RG.

PLoS One. 2012;7(4):e34531. doi: 10.1371/journal.pone.0034531. Epub 2012 Apr 5.

41.

A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer.

Whitehead J, Thygesen H, Jaki T, Davies S, Halford S, Turner H, Cook N, Jodrell D.

Stat Med. 2012 Aug 15;31(18):1931-43. doi: 10.1002/sim.5331. Epub 2012 Apr 11.

PMID:
22495759
42.

DNA looping by FokI: the impact of twisting and bending rigidity on protein-induced looping dynamics.

Laurens N, Rusling DA, Pernstich C, Brouwer I, Halford SE, Wuite GJ.

Nucleic Acids Res. 2012 Jun;40(11):4988-97. doi: 10.1093/nar/gks184. Epub 2012 Feb 28.

43.

DNA looping by FokI: the impact of synapse geometry on loop topology at varied site orientations.

Rusling DA, Laurens N, Pernstich C, Wuite GJ, Halford SE.

Nucleic Acids Res. 2012 Jun;40(11):4977-87. doi: 10.1093/nar/gks183. Epub 2012 Feb 23.

44.

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.

Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, Ross P, Halford S, Peters J, Balkissoon J, Chaplin DJ, Padhani AR, Rustin GJ.

Clin Cancer Res. 2012 Mar 1;18(5):1415-25. doi: 10.1158/1078-0432.CCR-11-2414. Epub 2012 Jan 10.

45.

Vertebrate ancient opsin photopigment spectra and the avian photoperiodic response.

Davies WI, Turton M, Peirson SN, Follett BK, Halford S, Garcia-Fernandez JM, Sharp PJ, Hankins MW, Foster RG.

Biol Lett. 2012 Apr 23;8(2):291-4. doi: 10.1098/rsbl.2011.0864. Epub 2011 Oct 26.

46.

Illuminating the reaction pathway of the FokI restriction endonuclease by fluorescence resonance energy transfer.

Pernstich C, Halford SE.

Nucleic Acids Res. 2012 Feb;40(3):1203-13. doi: 10.1093/nar/gkr809. Epub 2011 Oct 12.

47.

Functional diversity of melanopsins and their global expression in the teleost retina.

Davies WI, Zheng L, Hughes S, Tamai TK, Turton M, Halford S, Foster RG, Whitmore D, Hankins MW.

Cell Mol Life Sci. 2011 Dec;68(24):4115-32. doi: 10.1007/s00018-011-0785-4. Epub 2011 Aug 11.

PMID:
21833582
48.

Focus on molecules: cytochrome P450 family 4, subfamily V, polypeptide 2 (CYP4V2).

Mackay DS, Halford S.

Exp Eye Res. 2012 Sep;102:111-2. doi: 10.1016/j.exer.2011.06.019. Epub 2011 Jul 2. No abstract available.

PMID:
21745470
49.

Concerted action at eight phosphodiester bonds by the BcgI restriction endonuclease.

Marshall JJ, Smith RM, Ganguly S, Halford SE.

Nucleic Acids Res. 2011 Sep 1;39(17):7630-40. doi: 10.1093/nar/gkr453. Epub 2011 Jun 7.

50.

The reaction mechanism of FokI excludes the possibility of targeting zinc finger nucleases to unique DNA sites.

Halford SE, Catto LE, Pernstich C, Rusling DA, Sanders KL.

Biochem Soc Trans. 2011 Apr;39(2):584-8. doi: 10.1042/BST0390584. Review.

PMID:
21428944

Supplemental Content

Loading ...
Support Center